Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.30 - $15.50
Previous CloseN/A
Volume49.40K
Average Volume (3M)640.67K
Market Cap
$640.34M
Enterprise Value$322.51M
Total Cash (Recent Filing)$3.90M
Total Debt (Recent Filing)$6.57M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Jul 03, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding49,715,637
10 Day Avg. Volume564,223
30 Day Avg. Volume640,667
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.74
Enterprise Value/Ebitda-1.84
Forecast
1Y Price Target
$27.38Price Target Upside112.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
KalVista Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Market PositionSebetralstat is well-positioned to become the first commercially available oral on-demand HAE therapy in Japan.
Partnerships And AgreementsKalVista entered into a licensing agreement with Kaken Pharmaceutical to commercialize sebetralstat in Japan, bringing in incremental non-dilutive funding.
Regulatory ProgressPalleiko expressed continued confidence in the regulatory review process for sebetralstat, reiterating that the June PDUFA remains on track with no indication of delays or adcom review.
Bears Say
Competitive LandscapeThe competitive landscape for rare disease treatments poses challenges, as other companies are also advancing their drug development efforts.
Tariff ExposureThe company does not expect potential tariff exposure to materially impact US commercialization due to sebetralstat’s IP being owned and maintained in the UK, with API manufactured in the EU.
---
Ownership Overview
11.79% Insiders
15.56% Mutual Funds
0.22% Other Institutional Investors
63.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $15.50 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $640.34M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Jul 03, 2025 which is in 68 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Mar 12, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.054.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -0.85.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 49,715,637 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went up 0.161%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
---
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.38 (112.58% Upside)
$27.38 (112.58% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 664.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
-150.50%
Trailing 12-Months
Asset Growth
142.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
---
KALV Stock 12 Month Forecast
Average Price Target
$27.38
▲(112.58% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Dianthus Therapeutics
―
Replimune Group
―
LENZ Therapeutics
―
GH Research
―
Best Analysts Covering KALV
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+17.70%
reiterated a buy rating 18 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +17.70% per trade.
---